Oculis Holding AG OCS
Annual
Quarterly
No annual revenue total was found in Oculis Holding AG's SEC filings.
Oculis Holding AG (OCS) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
3.41M
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OCS (Nasdaq), OCSAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zug, Switzerland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1953530
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 10, 2026 | Aug 10, 2026 |
| 6-K | Current report (foreign issuer) | Aug 6, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jun 25, 2026 | Jun 25, 2026 |
| 6-K | Current report (foreign issuer) | Jun 1, 2026 | May 29, 2026 |
All 138 Oculis Holding AG SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.